Auris Medical Holding Ltd (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address unmet medical needs in neurotology and central nervous system disorders, announced the formation of a Scientific Advisory Board (SAB) for its tinnitus research and development programs.
“We are delighted to have several world-renowned tinnitus experts join Auris Medical as advisors as we are preparing to advance our various tinnitus projects through further clinical and pre-clinical development,” said Thomas Meyer, Auris Medical’s Founder, Chairman, and CEO. “There continues to be a strong unmet medical need amongst tinnitus sufferers worldwide, and we look forward to bringing novel therapeutics to patients. Thanks to the support from our new Scientific Advisory Board and the learnings from our late-stage trials with Keyzilen, we feel that we are in a good position to take Keyzilen, as well as our early-stage projects, forward.”
The appointments to Auris Medical’s Tinnitus SAB include:
- Wolfgang Arnold, professor emeritus, former director of the Department of Otolaryngology, Head and Neck Surgery of the Technical University of Munich, Germany
- David Baguley, PhD, MBA, professor in hearing sciences, faculty of medicine & health sciences, University of Nottingham, UK
- Richard Salvi, SUNY distinguished professor and director for the Center for Hearing and Deafness at the University at Buffalo, New York
- Hinrich Staecker, MD, PhD, professor, director, Division Otology/Neurotology, University of Kansas, Kan
The Company aims to implement the further development of Keyzilen as well as its early-stage tinnitus programs with non-dilutive funding.
Source: Auris Medical